Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: A meta-analysis

JAMA

Volumn 292, Issue 3, 2004, Pages 362-366

  Montalescot, Gilles ^a   Borentain, Maria ^a   Payot, Laurent ^a   Collet, Jean Philippe ^a   Thomas, Daniel ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR;

ACUTE HEART INFARCTION; ADULT; AGED; BLOOD CLOT LYSIS; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEART MUSCLE REPERFUSION; HEART REINFARCTION; HUMAN; MAJOR CLINICAL STUDY; MEDLINE; META ANALYSIS; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; VASCULAR PATENCY; ARTICLE; DRUG ANTAGONISM; FIBRINOLYTIC THERAPY; HEART INFARCTION; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOLYTIC THERAPY; TIME FACTORS;

EID: 3142708764     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.3.362     Document Type: Review

References (33)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361:13-20.
2. Dalby M, Bouzamondo A, Lechat P, Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003;108:1809-1814.
3. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895-1903.
4. Brener SJ, Barr LA, Burchenal JE, et al, for the Re-oPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Randomized, placebo controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 1998;98:734-741.
5. Stone GW, Grines CL, Cox DA, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346:957-966.
6. Neumann FJ, Kastrati A, Schmitt C, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000;35:915-921.
7. Antoniucci D, Rodriguez A, Hempel A, et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocardial infarction. J Am Coll Cardiol. 2003;42:1879-1885.
8. Topol EJ, Neumann FJ, Montalescot G. A preferred reperfusion strategy for acute myocardial infarction. J Am Coll Cardiol. 2003;42:1886-1889.
9. Van't Hof AWJ, Ernst N, DeBoer MJ, et al. Facilitation of primary coronary angioplasty by early start of a glycoprotein 2b/3a inhibitor: results of the Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) trial. Eur Heart J. 2004;25:837-846.
10. Lee DP, Herity NA, Hiatt BL, et al. Adjunctive platelet glycoprotein IIb/IIIa receptor inhibition with tirofiban before primary angioplasty improves angiographic outcomes: results of the Tirofiban Given in the Emergency Room before Primary Angioplasty (TIGER-PA) pilot trial. Circulation. 2003;107:1497-1501.
11. Cutlip DE, Ricciardi MJ, Frederick SL, et al. Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction. Am J Cardiol. 2003;92:977-980.
12. Zorman S, Zorman D, Noc M. Effects of abciximab pretreatment in patients with acute myocardial infarction undergoing primary angioplasty. Am J Cardiol. 2002;90:533-536.
13. Arntz H-R, Schroder JF, Pels K, et al. Prehospital versus periprocedural administration of abciximab in STEMI: early and late results from the randomised REOMOBILE-study. Eur Heart J. 2003;24(abstract suppl):268.
14. Mesquita Gabriel H, Oliveira J, Canas da Silva P, et al. Early administration of abciximab bolus in the emergency room improves microperfusion after primary percutaneous coronary intervention, as assessed by TIMI frame count: results of the ERAMI trial. Eur Heart J. 2003;24(abstract suppl):543.
15. Cucherat M, Boissel JP, Leizorovicz A, Haugh MC. EasyMA: a program for the meta-analysis of clinical trials. Comput Methods Programs Biomed. 1997;53:187-190.
16. Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory: the PRAGUE study. Eur Heart J. 2000;21:823-831.
17. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the CAP-TIM randomized clinical trial. Circulation. 2003;108:2851-2856.
18. Van den Merkhof LF, Zijlstra F, Olsson H, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous translumlnal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999;33:1528-1532.
19. Glatt B, Luycx-Bore A, Guyon P, et al. Pre-hospitalization treatment with abciximab in the preparation of patients for primary angioplasty in the acute phase of myocardial infarct: immediate and long-term (one month) results. Arch Mal Coeur Vaiss. 1999;92:1301-1308.
20. Makkar R, Goff B, Eigler N, et al. Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion of acute myocardial infarction: results of ReoMI pilot study. Catheter Cardiovasc Interv. 1999;48:430-434.
21. Antman EM, Giugliano R, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI)14 trial. Circulation. 1999;99:2720-2732.
22. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials, Circulation. 2001;104;636-641.
23. The GUSTO investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery, patency, ventricular function and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
24. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
25. De Luca G, Suryapranata H, Zijlstra F, et al. Symptom-onset-to-balloon time and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2003;42:991-997.
26. Cannon CP, Gibson CM, Lambrew CT, et al. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000;283:2941-2947.
27. Antoniucci D, Valenti R, Migliorini A, et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol. 2002;89:1248-1252.
28. Brodie BR, Stuckey TD, Wall TC, et al. Importance of time to reperfusion for 30-day and late survival and recovery of left ventricular function after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1998;32:1312-1319.
29. Anderson KM, Califf RM, Stone GW, et al. Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. J Am Coll Cardiol. 2001;37:2059-2065.
30. Lincoff AM, Califf RM, Topol EJ. Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. J Am Coll Cardiol. 2000;35:1103-1115.
31. Collet JP, Montalescot G, Lesty C, et al. Disaggregation of in vitro pre-formed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol. 2001;21:142-148.
32. Collet JPh, Montalescot G, Lesty CL, et al. Effects of abciximab on the architecture of platelet-rich clot in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001;103:2328-2331.
33. Kastrati A, Mehilli J, Schlotterbeck K, et al. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004;291:947-954.